Fibrostenotic inflammatory bowel disease / Florian Rieder, editor.
This book provides a comprehensive account of the pathogenesis and treatment of intestinal fibrosis, covering both the clinical and molecular aspects of the disease. It begins by describing the epidemiology and genetics of fibrostenosing IBD in Crohn’s disease and Ulcerative colitis as well as the e...
Saved in:
| Online Access: |
Full Text (via Springer) |
|---|---|
| Other Authors: | |
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
[2018]
|
| Subjects: |
Table of Contents:
- Intro; Foreword; Foreword; Contents; Chapter 1: Fibrostenotic Inflammatory Bowel Disease: A Cinderella Story; References; Chapter 2: Epidemiology and Natural History of Fibrostenosing Inflammatory Bowel Disease; 2.1 Introduction; 2.2 Epidemiology of Fibrostenosing Inflammatory Bowel Disease; 2.2.1 Crohn's Disease; 2.2.2 Ulcerative Colitis; 2.3 Natural History of Fibrostenosing Inflammatory Bowel Disease; 2.3.1 Risk and Prognostic Factors Associated with Fibrostenosis in Crohn's Disease; 2.3.2 Clinical Manifestations and Disease Progression of Fibrostenosis in Crohn's Disease.
- 2.3.3 Risk and Prognostic Factors Associated with Fibrostenosis in Ulcerative Colitis2.3.4 Clinical Manifestations and Disease Progression of Fibrostenosis in Ulcerative Colitis; 2.4 Pitfalls in Depicting Incidence and Natural History of Fibrostenosis Disease; References; Chapter 3: Genetic Influences on the Development of Fibrosis in Inflammatory Bowel Disease; 3.1 Introduction; 3.2 Genetics and Fibrosis in Crohn's Disease; 3.2.1 Bacterial Sensing; 3.2.1.1 Nucleotide-Binding Oligomerization Domain-Containing Protein 2, NOD2; 3.2.1.2 Toll-Like Receptors, TLRs.
- 3.2.8 Other Processes3.3 The Combined Action of the Known Susceptibility Variants; 3.4 Genetics and Fibrosis in Paediatric CD; 3.5 Genetics and Fibrosis in Ulcerative Colitis; 3.6 Genetics and Fibrosis Around the World; 3.7 Clinical Implications of the Found Associations; 3.8 Conclusions and Future Directions; References; Chapter 4: Epigenetic Regulation of Intestinal Fibrosis; 4.1 Introduction; 4.2 Genetics; 4.3 Epigenetics; 4.4 Epigenetics and Fibrosis; 4.5 DNA Methylation; 4.6 DNA Methylation and Fibrosis; 4.7 Histone Modifications of DNA and Post-Translational Modifications of Proteins.
- 3.2.2 Autophagy: Autophagy-Related 16-like 1, ATG16L13.2.3 Antigen Presentation: Major Histocompatibility Complex (MHC); 3.2.4 Cytokines and Their Receptors; 3.2.4.1 Interleukin-23 Receptor, IL-23R; 3.2.4.2 Fractalkine Receptor 1, CX3CR1; 3.2.4.3 Transforming Growth Factor Beta (TGF-β); 3.2.4.4 Angiotensinogen; 3.2.4.5 Tumour Necrosis Factor Alpha (TNFα); 3.2.5 Epithelial Barrier: Membrane Associated Guanylate Kinase, WW and PDZ Domain Containing 1, MAGI1; 3.2.6 Cell Signalling: Janus Kinase 2 (JAK2); 3.2.7 Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs (TIMPs)
- 4.8 Histone Modifications and Fibrosis4.9 MicroRNA; 4.10 MicroRNA and Fibrosis; 4.11 Long Non-Coding RNA and Fibrosis; 4.12 Summary; References; Chapter 5: Cytokine and Anti-Cytokine Agents as Future Therapeutics for Fibrostenosing IBD; 5.1 Introduction; 5.2 "Inflammatory" Cytokines; 5.2.1 TNFα; 5.2.2 Th1 Cytokines; 5.2.3 IL-1 Cytokines; 5.2.4 Th2 Cytokines; 5.2.5 Th17 Cytokines; 5.2.6 TL1A; 5.3 "Regulatory" Cytokines; 5.3.1 TGFβ; 5.3.2 IL-10; 5.4 Concluding Remarks; References; Chapter 6: Inflammation-Independent Mechanisms of Intestinal Fibrosis: The Role of the Extracellular Matrix.